Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan N Frone

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Human Mutation|October 24, 2018
Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysisKelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Human Mutation|April 19, 2019
Response to: Concern regarding classification of germlineTP53 variants as likely pathogenicKelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Cell Death and Differentiation|March 30, 2022
The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer InstituteKelvin César de Andrade, Elaine E Lee, Elise M Tookmanian, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 29, 2026
Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainmentJung Kim, Gina Ney, Megan N Frone, et al.
Medrxiv : the Preprint Server for Health Sciences|January 13, 2025
Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genesJung Kim, Gina Ney, Megan N Frone, et al.
HGG Advances|October 1, 2023
Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variantsKelvin C de Andrade, Natasha T Strande, Jung Kim, et al.
JCO Precision Oncology|October 23, 2025
Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni SyndromeAsaf Maoz, Nan Chen, Puja Umaretiya, et al.
Human Mutation|December 10, 2020
Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variantsCristina Fortuno, Kristy Lee, Magali Olivier, et al.
Human Mutation|December 12, 2023
Specifications of the ACMG/AMP Variant Classification Guidelines for Germline <i>DICER1</i> Variant CurationJessica N Hatton, Megan N Frone, Hannah C Cox, et al.
JCO Precision Oncology|September 14, 2020
Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor StudyLindsay M Morton, Danielle M Karyadi, Stephen W Hartley, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Human Mutation|October 24, 2018
Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysisKelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Human Mutation|April 19, 2019
Response to: Concern regarding classification of germlineTP53 variants as likely pathogenicKelvin C de Andrade, Megan N Frone, Talia Wegman-Ostrosky, et al.
Cell Death and Differentiation|March 30, 2022
The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer InstituteKelvin César de Andrade, Elaine E Lee, Elise M Tookmanian, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|March 29, 2026
Cancer risk in adults with pathogenic germline variants in RAS/MAPK genes using genomic ascertainmentJung Kim, Gina Ney, Megan N Frone, et al.
Medrxiv : the Preprint Server for Health Sciences|January 13, 2025
Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genesJung Kim, Gina Ney, Megan N Frone, et al.
HGG Advances|October 1, 2023
Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variantsKelvin C de Andrade, Natasha T Strande, Jung Kim, et al.
JCO Precision Oncology|October 23, 2025
Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni SyndromeAsaf Maoz, Nan Chen, Puja Umaretiya, et al.
Human Mutation|December 10, 2020
Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variantsCristina Fortuno, Kristy Lee, Magali Olivier, et al.
Human Mutation|December 12, 2023
Specifications of the ACMG/AMP Variant Classification Guidelines for Germline <i>DICER1</i> Variant CurationJessica N Hatton, Megan N Frone, Hannah C Cox, et al.
JCO Precision Oncology|September 14, 2020
Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor StudyLindsay M Morton, Danielle M Karyadi, Stephen W Hartley, et al.
Pageof 3